THELIN TABLET
Land: Canada
Sprog: engelsk
Kilde: Health Canada
Produktets egenskaber
(SPC)
13-05-2010
Nogle dokumenter til dette produkt er ikke tilgængelige i øjeblikket, du kan sende en anmodning til vores kundeservice, og vi vil underrette dig, så snart vi er i stand til at få dem.
Send anmodning.
Send anmodning.
Aktiv bestanddel:
SITAXSENTAN SODIUM
Tilgængelig fra:
PFIZER CANADA ULC
ATC-kode:
C02KX03
INN (International Name):
SITAXENTAN
Dosering:
100MG
Lægemiddelform:
TABLET
Sammensætning:
SITAXSENTAN SODIUM 100MG
Indgivelsesvej:
ORAL
Enheder i pakken:
28
Recept type:
Prescription
Terapeutisk område:
MISCELLANEOUS VASODILATATING AGENTS
Produkt oversigt:
Active ingredient group (AIG) number: 0152215001; AHFS:
Autorisation status:
CANCELLED POST MARKET
Autorisation dato:
2011-04-30
Produktets egenskaber
_ _
_ _
_PR_
_THELIN_
_® _
_(sitaxsentan sodium tablets) Product Monograph _
_Page 1 of 28_
PRODUCT MONOGRAPH
PR
THELIN
®
(sitaxsentan sodium tablets)
100 mg
Endothelin receptor antagonist
® Registered trademark of Encysive Pharmaceuticals Inc.
Pfizer Canada Inc.
17 300 Trans-Canada Highway
Kirkland, Quebec H9J 2M5
Date of preparation:
April 26, 2010
Submission Control Number: 134705
_ _
_ _
_PR_
_THELIN_
_® _
_(sitaxsentan sodium tablets) Product Monograph _
_Page 2 of 28_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL
INFORMATION................................................... 3
SUMMARY OF PRODUCT INFORMATION
............................................................. 3
INDICATIONS AND CLINICAL
USE.........................................................................
3
CONTRAINDICATIONS
..............................................................................................
3
DOSAGE AND
ADMINISTRATION.........................................................................
13
OVERDOSAGE:
..........................................................................................................
14
ACTION AND CLINICAL PHARMACOLOGY
....................................................... 15
STORAGE AND
STABILITY.....................................................................................
16
DOSAGE FORMS, COMPOSITION AND PACKAGING
........................................ 16
PART II: SCIENTIFIC
INFORMATION........................................................................
18
PHARMACEUTICAL
INFORMATION.....................................................................
18
CLINICAL
TRIALS.....................................................................................................
19
DETAILED
PHARMACOLOGY................................................................................
21
TOXICOLOGY
............................................................................................................
24
REFERENCES
.................................................................
Læs hele dokumentet
